Cytotoxicity Profiling and IC₅₀ Determination of Madecassoside-Loaded Ultra-Small Unilamellar Nanocarrier System on Keloid-derived fibroblast cell lines: an MTT Assay and Cell Viability AnalysisViability Analysis.

Objective: To evaluate the in vitro cytotoxicity of a madecassoside-loaded ultra-small unilamellar nanocarrier system (MU) against keloid-derived fibroblasts and to compare it with that of the empty carrier and pure madecassoside. Design: In vitro experimental study using keloid-derived fibroblasts and the MTT colorimetric assay; each treatment was performed in triplicate. Intervention: MU, prepared from virgin coconut oil (VCO), soy lecithin and Tween 80 by sonication-aided emulsification, its empty carrier and pure madecassoside were applied to the cells at 10, 20, 30 and 40 µg/mL for 72 h. Main outcome measures: Cell viability (percentage of untreated control), the half-maximal inhibitory concentration (IC50) calculated by semilogarithmic linear regression, and cell morphology under an inverted microscope. Groups were compared by two-way ANOVA with Bonferroni post hoc test. Results: MU reduced fibroblast viability in a concentration-dependent manner, with an IC50 of 29.77 µg/mL compared with 58.21 µg/mL for the empty carrier and 78.80 µg/mL for pure madecassoside (the latter two extrapolated beyond the highest tested concentration). At 30 µg/mL, viability after MU treatment was significantly lower than after pure madecassoside (65.1% vs 104.4%; p < 0.05). MU was the only sample that reduced viability below 50% within the tested range. Conclusion: Loading madecassoside into the ultra-small unilamellar nanocarrier increased its cytotoxic potential against keloid fibroblasts, as reflected by an approximately 2.6-fold lower IC50 than that of pure madecassoside, with the carrier itself contributing partly to this effect. Keywords: madecassoside; ultra-small unilamellar nanocarrier; keloid fibroblast; MTT assay; IC50; cytotoxicity

Authors

Publication Details

Journal
Journal of Drug Delivery and Therapeutics
Published
2026-11-15
DOI
https://doi.org/10.22270/jddt.v16i11.8092
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cytotoxicity Profiling and IC₅₀ Determination of Madecassoside-Loaded Ultra-Small Unilamellar Nanocarrier System on Keloid-derived fibroblast cell lines: an MTT Assay and Cell Viability AnalysisViability Analysis.

Henny Lucida, Tommy Julianto, Ully Chairunisa, Hendriati Hendriati
Journal of Drug Delivery and Therapeutics
Advancements in Transdermal Drug Delivery
article

Cytotoxicity Profiling and IC₅₀ Determination of Madecassoside-Loaded Ultra-Small Unilamellar Nanocarrier System on Keloid-derived fibroblast cell lines: an MTT Assay and Cell Viability AnalysisViability Analysis.

Henny Lucida, Tommy Julianto, Ully Chairunisa, Hendriati Hendriati
article en

Abstract

Objective: To evaluate the in vitro cytotoxicity of a madecassoside-loaded ultra-small unilamellar nanocarrier system (MU) against keloid-derived fibroblasts and to compare it with that of the empty carrier and pure madecassoside. Design: In vitro experimental study using keloid-derived fibroblasts and the MTT colorimetric assay; each treatment was performed in triplicate. Intervention: MU, prepared from virgin coconut oil (VCO), soy lecithin and Tween 80 by sonication-aided emulsification, its empty carrier and pure madecassoside were applied to the cells at 10, 20, 30 and 40 µg/mL for 72 h. Main outcome measures: Cell viability (percentage of untreated control), the half-maximal inhibitory concentration (IC50) calculated by semilogarithmic linear regression, and cell morphology under an inverted microscope. Groups were compared by two-way ANOVA with Bonferroni post hoc test. Results: MU reduced fibroblast viability in a concentration-dependent manner, with an IC50 of 29.77 µg/mL compared with 58.21 µg/mL for the empty carrier and 78.80 µg/mL for pure madecassoside (the latter two extrapolated beyond the highest tested concentration). At 30 µg/mL, viability after MU treatment was significantly lower than after pure madecassoside (65.1% vs 104.4%; p < 0.05). MU was the only sample that reduced viability below 50% within the tested range. Conclusion: Loading madecassoside into the ultra-small unilamellar nanocarrier increased its cytotoxic potential against keloid fibroblasts, as reflected by an approximately 2.6-fold lower IC50 than that of pure madecassoside, with the carrier itself contributing partly to this effect. Keywords: madecassoside; ultra-small unilamellar nanocarrier; keloid fibroblast; MTT assay; IC50; cytotoxicity

Journal of Drug Delivery and TherapeuticsVol. 16(11)
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Cytotoxicity Profiling and IC₅₀ Determination of Madecassoside-Loaded Ultra-Small Unilamellar Nanocarrier System on Keloid-derived fibroblast cell lines: an MTT Assay and Cell Viability AnalysisViability Analysis. — Henny Lucida, Tommy Julianto, et al. · Journal of Drug Delivery and Therapeutics (2026) | TGRS Research Map | TGRS